The aim of this study was to estimate the outcome of adjuvant therapy as goserelin and tamoxifen in young patients with stage I-IIIa breast cancer. Retrospective study based on 71 pre-menopausal women younger than 40 years old with primary breast cancer, hormone receptorpositive, complemented by goserelin treatment for 2 years in combination with tamoxifen. Follow-up was to assess longitudinal survival rate. Results showed that all patients stopped menstruation after one Zoladex injection, with re-menstruation 7 months after stopping the injections. The recurrent/metastastic frequency is 14.1 percent. Disease-free survival rate at 2 years, 5 years were 98.6 percent, 85.9 percent, respectively. Survival in patient group without lymph node metastasis was 95.1 percent compared with 73.3 percent in those with lymph node metastasis. Patients with progesterone receptor - positive tumor had better survival than compared to those without this receptor. Overall survival and recurrence - free survival is 89.2 percent in the PR(+) group and 50 percent in PR(-) subgroup. Patients with HER2 (+) had a worse prognosis as compared with HER2(-) group, 70 percent survival with recurrent cancer compare to 93.5 percent.
- Đăng nhập để gửi ý kiến